The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
Abstract
The development of new blood vessels (angiogenesis) is required for many physiological processes including embryogenesis, wound healing and corpus luteum formation. Blood vessel neoformation is also important in the pathogenesis of many disorders, particularly rapid growth and metastasis of solid tumours. There are several potential mediators of tumour angiogenesis, including basic and acidic fibroblast growth factors, tumour necrosis factor-alpha and transforming factors-alpha and -beta. But it is unclear whether any of these agents actually mediates angiogenesis and tumour growth in vivo. Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen and an angiogenesis inducer released by a variety of tumour cells and expressed in human tumours in situ. To test whether VEGF may be a tumour angiogenesis factor in vivo, we injected human rhabdomyosarcoma, glioblastoma multiforme or leiomyosarcoma cell lines into nude mice. We report here that treatment with a monoclonal antibody specific for VEGF inhibited the growth of the tumours, but had no effect on the growth rate of the tumour cells in vitro. The density of vessels was decreased in the antibody-treated tumours. These findings demonstrate that inhibition of the action of an angiogenic factor spontaneously produced by tumour cells may suppress tumour growth in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 1993, it was reported that treatment with anti‐VEGF monoclonal antibodies resulted in a significant reduction in vessel density and a significant delay in tumor growth in nude mice carrying rhabdomyosarcoma, glioblastoma multiforme (GBM), and leiomyosarcoma xenografts.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [266]
Citations
Cites
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,598
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 5,000
Self-citationVascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,509
Folkman, J., & Shing, Y. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49853-0 · Cited by 2,651
Ferrara, N., & Henzel, W. J. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92678-8 · Cited by 2,269
Self-citationPlate, K. H., Breier, G., Weich, H. A., & Risau, W. (1992) · Nature · doi:10.1038/359845a0 · Cited by 2,262
Vascular Permeability Factor, an Endothelial Cell Mitogen Related to PDGF
Keck, P. J., Hauser, S. D., Krivi, G. G., Sanzo, K., Warren, T. G., Feder, J., & Connolly, D. T. (1989) · Science · doi:10.1126/science.2479987 · Cited by 2,058
Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J. C., & Abraham, J. A. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99049-6 · Cited by 1,988
Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins
Ferrara, N., Houck, K. A., Jakeman, L. B., & LEUNG, D. W. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-18 · Cited by 1,655
Self-citation
Flagged first, then by citations
1 of the 32 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Senger, D., Perruzzi, C. A., Feder, J. & Dvorak, H. F. Cancer Res. 46, 5629 (1986).
- Westphal, M. et al. Expl cell. Biol. 55, 152–161 (1987).
Cited by
Sorted by citations
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Self-citationThe biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Self-citationPaclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Risau, W. (1997) · Nature · doi:10.1038/386671a0 · Cited by 5,727
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,585
Self-citationAiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., JAMPEL, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,803
Self-citationVascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,788
Self-citationHeterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O’Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,661
Self-citationLong-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,521
Vascular endothelial growth factor (VEGF) and its receptors
Neufeld, G., Cohen, T., Gengrinovitch, S., & Gluzman‐Poltorak, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,511
OʼReilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,344
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,057
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Self-citationYang, J. C., Haworth, L. R., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,704
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Self-citationDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Self-citationSöker, S., Takashima, S., Miao, H. Q., Neufeld, G., & Klagsbrun, M. (1998) · Cell · doi:10.1016/s0092-8674(00)81402-6 · Cited by 2,493
Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Holash, J. A., Maisonpierre, P. C., Compton, D. L., Boland, P., Alexander, C., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,222
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,948
Holmgren, L., O’Reilly, M. S., & Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0295-149 · Cited by 1,891
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Vascular Endothelial Growth Factor and Angiogenesis
Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Van Oosterom, A. T., & De Bruijn, E. A. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.3 · Cited by 1,824
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Shibuya, M. (2011) · Genes & Cancer · doi:10.1177/1947601911423031 · Cited by 1,850
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,596
Self-citationDvorak, H. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.088 · Cited by 1,600
VEGF and the quest for tumour angiogenesis factors
Ferrara, N. (2002) · Nature Reviews Cancer · doi:10.1038/nrc909 · Cited by 1,536
Self-citationThe unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
Brown, J. M., & Giaccia, A. J. (1998) · PubMed · Cited by 1,499
Kendall, R. L., & Thomas, K. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10705 · Cited by 1,419
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M., Marcom, P. K., Fehrenbacher, L., Dickler, M. N., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,303
Adamis, A. P., Miller, J. W., Bernal, M.-T., D’Amico, D. J., Folkman, J., Yeo, T.-K., & Yeo, K.-T. J. (1994) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)75794-0 · Cited by 1,297
Vascular Endothelial Growth Factor
Ferrara, N. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179663 · Cited by 1,308
Self-citationHypoxia-inducible expression of tumor-associated carbonic anhydrases.
Wykoff, C. C., Beasley, N. J. P., Watson, P. H., Turner, K., Pastorek, J., Sibtain, A., Wilson, G. D., Turley, H., Talks, K., Maxwell, P. H., et al. (2000) · PubMed · Cited by 1,260
VEGF-D promotes the metastatic spread of tumor cells via the lymphatics
Stacker, S. A., Caesar, C., Baldwin, M. E., Thornton, G. E., Williams, R. A., Prevo, R., Jackson, D. G., Nishikawa, S., Kubo, H., & Achen, M. G. (2001) · Nature Medicine · doi:10.1038/84635 · Cited by 1,249
The discovery of receptor tyrosine kinases: targets for cancer therapy
Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227
Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
Millauer, B., Shawver, L. K., Plate, K. H., Risaui, W., & Ullrich, A. (1994) · Nature · doi:10.1038/367576a0 · Cited by 1,225
Angiostatin induces and sustains dormancy of human primary tumors in mice
O’Reilly, M. S., Holmgren, L., Chen, C., & Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0696-689 · Cited by 1,170
Molecular and biological properties of vascular endothelial growth factor
Ferrara, N. (1999) · Journal of Molecular Medicine · doi:10.1007/s001099900019 · Cited by 1,153
Self-citationPericytes of the neurovascular unit: key functions and signaling pathways
Sweeney, M. D., Ayyadurai, S., & Zlokovic, B. V. (2016) · Nature Neuroscience · doi:10.1038/nn.4288 · Cited by 1,125
Park, J. E., Keller, G. A., & Ferrara, N. (1993) · Molecular Biology of the Cell · doi:10.1091/mbc.4.12.1317 · Cited by 1,123
Self-citationPark, J. E., Chen, H. H., Winer, J., Houck, K. A., & Ferrara, N. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47298-5 · Cited by 1,112
Self-citationRegulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.
Ravi, R. K., Mookerjee, B., Bhujwalla, Z. M., Sutter, T. R., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · PubMed Central · Cited by 1,099
The implications of angiogenesis for the biology and therapy of cancer metastasis
Fidler, I. J. (1994) · Cell · doi:10.1016/0092-8674(94)90187-2 · Cited by 1,099
Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J., Hankinson, O., Pugh, C. W., & Ratcliffe, P. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.8104 · Cited by 1,084
Role of vascular endothelial growth factor in regulation of physiological angiogenesis
Ferrara, N. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.280.6.c1358 · Cited by 1,094
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
Interleukin 6 Induces the Expression of Vascular Endothelial Growth Factor
Cohen, T., Nahari, D., Weiss-Cerem, L., Neufeld, G., & Levi, B.-Z. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.736 · Cited by 1,042
Takeshita, S., Zheng, L., Brogi, E., Kearney, M., Pu, L. L. Q., Bunting, S., Ferrara, N., Symes, J. F., & Isner, J. M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117018 · Cited by 1,034
Self-citationTen years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,074
Self-citationFong, T. A. T., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T., Kim, Y. H., Schreck, R., Wang, X., Risau, W., et al. (1999) · PubMed · Cited by 1,026
Pierce, E. A., Avery, R. L., Foley, E. D., Aiello, L. P., & Smith, L. E. H. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.3.905 · Cited by 1,029
Clinical applications of angiogenic growth factors and their inhibitors
Ferrara, N., & Alitalo, K. (1999) · Nature Medicine · doi:10.1038/70928 · Cited by 1,004
Self-citationTumor Induction of VEGF Promoter Activity in Stromal Cells
Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.-C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81731-6 · Cited by 996
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Ferrara, N., Hillan, K. J., & Novotny, W. F. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.132 · Cited by 1,006
Self-citationTumor angiogenesis: past, present and the near future
Kerbel, R. S. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.505 · Cited by 985
Circulating Tumor Cells in Patients with Breast Cancer Dormancy
Meng, S., Tripathy, D., Frenkel, E. P., Shete, S. S., Naftalis, E. Z., Huth, J. F., Beitsch, P. D., Leitch, M., Hoover, S. J., Euhus, D., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1110 · Cited by 969
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · Genes & Development · doi:10.1101/gad.14.1.34 · Cited by 967
Biological Roles of Fibroblast Growth Factor-2
Bikfalvi, A., Klein, S., Pintucci, G., & Rifkin, D. B. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0292 · Cited by 962
Kabbinavar, F. F., Schulz, J. J., McCleod, M., Patel, T. N., Hamm, J. T., Hecht, J. R., MASS, R. D., Perrou, B., Nelson, B. J., & Novotny, W. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.112 · Cited by 933
Ziche, M., Morbidelli, L., Choudhuri, R., Zhang, H. T., Donnini, S., Granger, H. J., & Bicknell, R. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119451 · Cited by 909
Gordon, M. S., Margolin, K. A., Talpaz, M., Sledge, G. W., Holmgren, E. B., Benjamin, R. S., Stalter, S., Shak, S., & Adelman, D. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.843 · Cited by 913
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G., & Goldberg, M. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10595 · Cited by 896
Intratumor microvessel density as a prognostic factor in cancer.
Weidner, N. (1995) · PubMed Central · Cited by 866
Gorski, D. H., Beckett, M. A., Jaskowiak, N. T., Calvin, D. P., Mauceri, H. J., Salloum, R. M., Seetharam, S., Koons, A., Hari, D. M., Kufe, D. W., et al. (1999) · PubMed · Cited by 862
Seghezzi, G., Patel, S., Ren, C. J., Gualandris, A., Pintucci, G., Robbins, E. S., Shapiro, R. L., Galloway, A. C., Rifkin, D. B., & Mignatti, P. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.141.7.1659 · Cited by 880
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849
Self-citationWood, J. M., Bold, G., Buchdunger, E., Cozens, R. M., Ferrari, S. M., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., et al. (2000) · PubMed · Cited by 844
Griffioen, A. W., & Molema, G. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01448-0 · Cited by 843
Nissen, N., Polverini, P. J., Koch, A. E., Volin, M. V., Gamelli, R. L., & DiPietro, L. A. (1998) · Europe PMC (PubMed Central) · Cited by 833
Improving the efficacy of antibody-based cancer therapies
Carter, P. M. (2001) · Nature reviews. Cancer · doi:10.1038/35101072 · Cited by 849
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
Whittaker, S. R., Marais, R., & Zhu, A. X. (2010) · Oncogene · doi:10.1038/onc.2010.236 · Cited by 841
Selective Requirement for Src Kinases during VEGF-Induced Angiogenesis and Vascular Permeability
Eliceiri, B. P., Paul, R., Schwartzberg, P. L., Hood, J. D., Leng, J., & Cheresh, D. A. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80221-x · Cited by 823
Mechanisms of normal and tumor-derived angiogenesis
Papetti, M., & Herman, I. M. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00389.2001 · Cited by 809
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Mancuso, M. R., Davis, R. B., Norberg, S. M., O’Brien, S., Sennino, B., Nakahara, T., Yao, V., Inai, T., Brooks, P. C., Freimark, B. D., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24612 · Cited by 814
Lymphangiogenesis and cancer metastasis
Stacker, S. A., Achen, M. G., Jussila, L., Baldwin, M. E., & Alitalo, K. K. (2002) · Nature reviews. Cancer · doi:10.1038/nrc863 · Cited by 798
Shibuya, M. (2012) · The Journal of Biochemistry · doi:10.1093/jb/mvs136 · Cited by 820
Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes
Gerber, H.-P., Condorelli, F., Park, J., & Ferrara, N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.38.23659 · Cited by 794
Self-citationHypoxia-inducible factor-1alpha is a positive factor in solid tumor growth.
Ryan, H. E., Poloni, M., McNulty, W., Elson, D., Gassmann, M., Arbeit, J. M., & Johnson, R. S. (2000) · PubMed · Cited by 778
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Kamba, T., Tam, B. Y. Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso, M. R., Norberg, S. M., O’Brien, S., Davis, R. B., Gowen, L. C., et al. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00133.2005 · Cited by 788
Rak, J. W., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., & Kerbel, R. S. (1995) · PubMed · Cited by 762
Inai, T., Mancuso, M. R., Hashizume, H., Baffert, F., Haskell, A., Bałuk, P., Hu‐Lowe, D. D., Shalinsky, D. R., Thurston, G., Yancopoulos, G. D., et al. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63273-7 · Cited by 769
Targeting the tumour vasculature: insights from physiological angiogenesis
Chung, A. S., Lee, J., & Ferrara, N. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2868 · Cited by 771
Self-citationRuckman, J., Green, L. S., Beeson, J., Waugh, S. M., Gillette, W. L., Henninger, D. D., Claesson, L., & Janjić, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20556 · Cited by 759
Holash, J. A., Wiegand, S. J., & Yancopoulos, G. D. (1999) · Oncogene · doi:10.1038/sj.onc.1203035 · Cited by 752
Role of vascular endothelial growth factor in the regulation of angiogenesis
Ferrara, N. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00610.x · Cited by 744
Self-citationTransforming growth factor-beta: Vasculogenesis, angiogenesis, and vessel wall integrity
Pepper, M. S. (1997) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(96)00048-2 · Cited by 737
Developmental and Pathological Angiogenesis
Chung, A. S., & Ferrara, N. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154002 · Cited by 745
Self-citationYuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., & Jain, R. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14765 · Cited by 719
Self-citationLee, S., Jilani, S. M., Nikolova, G. V., Carpizo, D. R., & Iruela‐Arispe, M. L. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200409115 · Cited by 733
Domingues, B., Lopes, J. M., Soares, P., & Pópulo, H. (2018) · ImmunoTargets and Therapy · doi:10.2147/itt.s134842 · Cited by 729
Warren, R. S., Yuan, H., Matli, M. R., Gillett, N. A., & Ferrara, N. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117857 · Cited by 694
Self-citationShrimali, R. K., Yu, Z., Theoret, M. R., Chinnasamy, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0153 · Cited by 677
Kabbinavar, F. F., Hambleton, J., Mass, R. D., Hurwitz, H. I., Bergsland, E., & Sarkar, S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.232 · Cited by 686
Vascular endothelial growth factor and its receptors
Klagsbrun, M., & D'Amore, P. A. (1996) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(96)00027-5 · Cited by 683
Metadata
- Authors
- Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N.
- Affiliations
- Genentech (US)
- Venue
- Nature
- Published
- 1993-04
- Volume
- 362
- Issue
- 6423
- Pages
- 841-844
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1969328947
- Cited by
- 3,605
- References
- 32
- Citations by year
- 2026: 22 · 2025: 25 · 2024: 43 · 2023: 47 · 2022: 53 · 2021: 55 · 2020: 55 · 2019: 54 · 2018: 89 · 2017: 101 · 2016: 81 · 2015: 78 · 2014: 98 · 2013: 110 · 2012: 137
- FWCI
- 32.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- vascular endothelial growth factor, angiogenesis, tumor angiogenesis, tumor growth inhibition, monoclonal antibodies, rhabdomyosarcoma, glioblastoma, leiomyosarcoma, tumor vasculature, nude mice, tumour metastasis
- MeSH terms
- Animals, Antibodies, Monoclonal, Cell Division, Female, Glioblastoma, Humans, Leiomyosarcoma, Lymphokines, Mice, Nude, Neoplasm Transplantation, Neoplasms, Experimental, Neovascularization, Pathologic, Rhabdomyosarcoma, Tumor Cells, Cultured, Endothelial Growth Factors, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
